Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Eli Lilly and Company
Julio Rosenstock; Juan Frias; Ania M Jastreboff; Yu Du; Jitong Lou; Sirel Gurbuz; Melissa K Thomas; Mark L Hartman; Axel Haupt; Zvonko Milicevic; Tamer Coskun